Search: onr:"swepub:oai:DiVA.org:uu-441708" > Bortezomib-Based In...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06299naa a2200673 4500 | |
001 | oai:DiVA.org:uu-441708 | |
003 | SwePub | |
008 | 210505s2021 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:146292024 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4417082 URI |
024 | 7 | a https://doi.org/10.1016/j.jtct.2020.11.0182 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1462920242 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Cornell, Robert F.u AbbVie, N Chicago, IL USA4 aut |
245 | 1 0 | a Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden |
264 | 1 | b Elsevier,c 2021 |
338 | a print2 rdacarrier | |
520 | a The benefits of pre-transplant induction chemotherapy in light chain (AL) amyloidosis, a low burden plasma cell (PC) neoplasm associated with multiorgan dysfunction, is debatable, although with the availability of bortezomib, this approach is being increasingly pursued. We analyzed the outcomes of AL amyloidosis patients undergoing autologous hematopoietic cell transplant between 2014 and 2018 that were reported to the Center for International Blood and Marrow Transplant Research database. Of 440 patients, 294 received bortezomib-based induction, and 146 received no induction. Patients receiving induction had greater PC burden compared to no induction (PC 10% or more, 39% versus 11%; P < .01). At 2 years, the induction group compared to no induction had lower relapse/progression: 13% (9% to 18%) versus 23% (16% to 32%) (P = .02); better progression-free survival (PFS): 82% (77% to 87%) versus 69% (61% to 77%) (P < .01); and similar overall survival (OS): 92% (88% to 95%) versus 89% (84% to 94%) (P = .22), findings that were confirmed on multivariate analysis. A subset analysis limited to patientswith <10% PC also showed superior relapse/progression (hazard ratio [HR],.43; 95% confidence interval [CI],.24 to.78; P < .01) and PFS (HR,.43; 95% CI,.26 to .72; P < .01) for induction compared to no induction. Thus, we conclude that pre-transplant bortezomib-based induction was associated with improved relapse/progression and PFS in AL amyloidosis. Longer survival follow-up is warranted, as OS was excellent in both cohorts at 2 years. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Bone marrow transplant | |
653 | a Hem malignancies | |
653 | a Myeloma | |
700 | 1 | a Fraser, Raphaelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Costa, Lucianou Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA4 aut |
700 | 1 | a Goodman, Staceyu Vanderbilt Univ, Med Ctr, Nashville, TN USA4 aut |
700 | 1 | a Estrada-Merly, Noelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Lee, Cindyu Royal Adelaide Hosp, Adelaide, SA, Australia4 aut |
700 | 1 | a Hildebrandt, Gerhardu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut |
700 | 1 | a Gergis, Usamau Thomas Jefferson Univ, Dept Med Oncol, Div Hematol Malignancies, Philadelphia, PA 19107 USA4 aut |
700 | 1 | a Farhadfar, Noshau Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA4 aut |
700 | 1 | a Freytes, César O.u Texas Transplant Inst, San Antonio, TX USA4 aut |
700 | 1 | a Kamble, Rammurti T.u Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA4 aut |
700 | 1 | a Krem, Maxwellu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut |
700 | 1 | a Kyle, Robert A.u Mayo Clin Rochester, Rochester, MN USA4 aut |
700 | 1 | a Lazarus, Hillard M.u Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA4 aut |
700 | 1 | a Marks, David I.u Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England4 aut |
700 | 1 | a Meehan, Kennethu Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA4 aut |
700 | 1 | a Patel, Sagar S.u Univ Utah, Blood & Marrow Transplant Program, Salt Lake City, UT USA4 aut |
700 | 1 | a Ramanathan, Muthalaguu UMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA4 aut |
700 | 1 | a Olsson, Richard F.u Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Wagner, John L.u Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA4 aut |
700 | 1 | a Kumar, Shajiu Mayo Clin Rochester, Rochester, MN USA4 aut |
700 | 1 | a Qazilbash, Muzaffar H.u MD Anderson Canc Ctr, Houston, TX USA4 aut |
700 | 1 | a Shah, Ninahu Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA4 aut |
700 | 1 | a Hari, Parameswaranu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a D'Souza, Anitau Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut |
710 | 2 | a AbbVie, N Chicago, IL USAb Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA4 org |
773 | 0 | t Transplantation and Cellular Therapyd : Elsevierg 27:3, s. 264.e1-264.e7q 27:3<264.e1-264.e7x 2666-6375x 2666-6367 |
856 | 4 | u https://doi.org/10.1016/j.jtct.2020.11.018 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-441708 |
856 | 4 8 | u https://doi.org/10.1016/j.jtct.2020.11.018 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:146292024 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.